VC-backed Aerie Pharma prices IPO – Fortune

According to Fortune, Aerie Pharmaceuticals has priced its IPO of 5.25 million shares at between $12 to $14 per share. The company plans to trade the stock on the NASDAQ under the ticker symbol “AERI.” RBC Capital Markets and Stifel are acting as lead underwriters. With offices in New Jersey, California and North Carolina, Aerie Pharmaceuticals is a developer of drugs that treat glaucoma patients. The company is backed by Alta Partners, TPG Ventures, Clarus Ventures, Sofinnova Ventures and Osage Ventures.